Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype

Journal of Cellular Biochemistry

Volumn 113, Issue 1, 2012, Pages 282-292

  Pierce, Adam D ^a   Anglin, Ian E ^a   Vitolo, Michele I ^a   Mochin, Maria T ^a   Underwood, Karen F ^a   Goldblum, Simeon E ^a   Kommineni, Sravya ^a   Passaniti, Antonino ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; Endothelial cell; Glucose; Phosphorylation; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; GLUCOSE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR RUNX2;

ANGIOGENESIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DNA BINDING; ENDOTHELIUM CELL; GENE REPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; WOUND HEALING;

CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC;

EID: 84055222576     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23354     Document Type: Article

References (39)

1. Antelman D, Perry S, Hollingsworth R, Gregory RJ, Driscoll B, Fung YK, Bookstein R,. 1997. Engineered mutants of pRB with improved growth suppression potential. Oncogene 15: 2855-2866. (Pubitemid 28004575)
2. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH,. 2004. p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther 3: 221-225. (Pubitemid 41350908)
3. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC,. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64: 4506-4513. (Pubitemid 38856922)
4. Berman SD, Yuan TL, Miller ES, Lee EY, Caron A, Lees JA,. 2008. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 6: 1440-1451.
5. Blyth K, Cameron ER, Neil JC,. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5: 376-387. (Pubitemid 40637829)
6. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA,. 2010. Rb regulates fate choice and lineage commitment in vivo. Nature 466: 1110-1114.
7. D'Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, Passaniti A,. 2009. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J Biol Chem 284: 17947-17955.
8. Dudley AC, Klagsbrun M,. 2009. Tumor endothelial cells have features of adult stem cells. Cell Cycle 8: 236-238.
9. Folkman J,. 2007. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286. (Pubitemid 46505878)
10. Fu J, Wang W, Liu YH, Lu H, Luo Y,. 2011. In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on human endothelial cells. BMC Cancer 11: 227.
11. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ,. 2005. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280: 20274-20285. (Pubitemid 40776725)
12. Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, Roca H, Franceschi RT,. 2009. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 284: 32533-32543.
13. Harrington KS, Javed A, Drissi H, McNeil S, Lian JB, Stein JL, Van Wijnen AJ, Wang YL, Stein GS,. 2002. Transcription factors RUNX1/AML1 and RUNX2/Cbfa1 dynamically associate with stationary subnuclear domains. J Cell Sci 115: 4167-4176. (Pubitemid 35446811)
14. Inman CK, Shore P,. 2003. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278: 48684-48689. (Pubitemid 41079508)
15. Karsenty G,. 2001. Minireview: Transcriptional control of osteoblast differentiation. Endocrinology 142: 2731-2733. (Pubitemid 32575505)
16. Kerbel RS,. 2008. Tumor angiogenesis. N Engl J Med 358: 2039-2049. (Pubitemid 351656458)
17. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y,. 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. Embo J 15: 7060-7069. (Pubitemid 27023276)
18. Kwon TG, Zhao X, Yang Q, Li Y, Ge C, Zhao G, Franceschi RT,. 2011. Physical and functional interactions between Runx2 and HIF-1alpha induce vascular endothelial growth factor gene expression. J Cell Biochem 2011, July 25, Epub ahead of pring.
19. Li Y, Ge C, Franceschi RT,. 2010. Differentiation-dependent association of phosphorylated extracellular signal-regulated kinase with the chromatin of osteoblast-related genes. J Bone Miner Res 25: 154-163.
20. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK,. 2010. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 70: 7166-7175.
21. Namba K, Abe M, Saito S, Satake M, Ohmoto T, Watanabe T, Sato Y,. 2000. Indispensable role of the transcription factor PEBP2/CBF in angiogenic activity of a murine endothelial cell MSS31. Oncogene 19: 106-114. (Pubitemid 30066356)
22. Nimmo R, Antebi A, Woollard A,. 2005. mab-2 encodes RNT-1, a C. elegans Runx homologue essential for controlling cell proliferation in a stem cell-like developmental lineage. Development 132: 5043-5054. (Pubitemid 41764015)
23. Potenta S, Zeisberg E, Kalluri R,. 2008. The role of endothelial-to- mesenchymal transition in cancer progression. Br J Cancer 99: 1375-1379.
24. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB,. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25: 8581-8591. (Pubitemid 41369178)
25. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS,. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25: 589-600. (Pubitemid 46071865)
26. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A,. 2006. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 281: 7118-7128. (Pubitemid 43847476)
27. Rajgopal A, Young DW, Mujeeb KA, Stein JL, Lian JB, van Wijnen AJ, Stein GS,. 2007. Mitotic control of RUNX2 phosphorylation by both CDK1/cyclin B kinase and PP1/PP2A phosphatase in osteoblastic cells. J Cell Biochem 100: 1509-1517. (Pubitemid 46515582)
28. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, Remacle J,. 2001. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 29: E21.
29. Ryu JM, Lee MY, Yun SP, Han HJ,. 2010. High glucose regulates cyclin D1/E of human mesenchymal stem cells through TGF-beta1 expression via Ca2+/PKC/MAPKs and PI3K/Akt/mTOR signal pathways. J Cell Physiol 224: 59-70.
30. San Martin IA, Varela N, Gaete M, Villegas K, Osorio M, Tapia JC, Antonelli M, Mancilla EE, Pereira BP, Nathan SS, Lian JB, Stein JL, Stein GS, van Wijnen AJ, Galindo M,. 2009. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. J Cell Physiol 221: 560-571.
31. Semenza GL,. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732. (Pubitemid 37328811)
32. Shen R, Wang X, Drissi H, Liu F, O'Keefe RJ, Chen D,. 2006. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem 281: 16347-16353.
33. Sun L, Vitolo M, Passaniti A,. 2001. Runt-related gene 2 in endothelial cells: Inducible expression and specific regulation of cell migration and invasion. Cancer Res 61: 4994-5001. (Pubitemid 32681526)
34. Sun L, Vitolo M, Qiao M, Anglin I, Passaniti A,. 2004. Regulation of TGFß1-mediated growth inhibition and apoptosis by RUNX2 isoforms. Oncogene 23: 4722-4734. (Pubitemid 38859460)
35. Tsuji K, Komori T, Noda M,. 2004. Aged mice require full transcription factor, Runx2/Cbfa1, gene dosage for cancellous bone regeneration after bone marrow ablation. J Bone Miner Res 19: 1481-1489. (Pubitemid 41094349)
36. Vander Heiden MG, Cantley LC, Thompson CB,. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033.
37. Vitolo MI, Anglin IE, Mahoney WM, Jr, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A,. 2007. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 6: 856-863. (Pubitemid 351574974)
38. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X,. 2002. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982-7992. (Pubitemid 35217306)
39. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR,. 2001. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 106: 97-106. (Pubitemid 32701077)